Cansino Biotech announced on the Hong Kong Stock Exchange that the company is concerned about recent developments in mRNA technology in the market. The mRNA platform is one of our key technology platforms. The company is developing mRNA preventive vaccines and therapeutic biological products, as well as related delivery systems. In the field of treatment, the company is promoting research and development of mRNA vaccines for the treatment of indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of in-viVocar related therapies, which are currently in the early stages.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.